来源：环球市场播报 诺和诺德的最新指引意味着，该公司今年将录得九年来首次年度销售下滑，上次这样下滑还是在2017 年，当时是美国胰岛素市场的价格战所致。 诺和诺德CEO Mike Doustdar表示，2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全 球GLP-1市场预计将继续扩张，但美国总统特朗普推动的"最惠国价格"政策，以及司美格鲁肽在多个国 际市场专利到期的影响，将对营收造成显著冲击。 诺和诺德（NVO）周四早盘下跌6.3%，此前该公司警告美国定价压力与专利到期风险。 ...

诺和诺德（NVO）周四早盘下跌6.3%，此前该公司警告美国定价压力与专利到期风险。 诺和诺德的最新指引意味着，该公司今年将录得九年来首次年度销售下滑，上次这样下滑还是在2017 年，当时是美国胰岛素市场的价格战所致。 诺和诺德CEO Mike Doustdar表示，2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全 球GLP-1市场预计将继续扩张，但美国总统特朗普推动的"最惠国价格"政策，以及司美格鲁肽在多个国 际市场专利到期的影响，将对营收造成显著冲击。 诺和诺德的最新指引意味着，该公司今年将录得九年来首次年度销售下滑，上次这样下滑还是在2017 年，当时是美国胰岛素市场的价格战所致。 责任编辑：张俊 SF065 责任编辑：张俊 SF065 诺和诺德CEO Mike Doustdar表示，2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全 球GLP-1市场预计将继续扩张，但美国总统特朗普推动的"最惠国价格"政策，以及司美格鲁肽在多个国 际市场专利到期的影响，将对营收造成显著冲击。 诺和诺德（NVO）周四早盘下跌6.3%，此前该公司警告美国定价压力与专利到期风险。 ...

面对市场激烈竞争与2026年销售下滑预期，诺和诺德CEO坦言明星减肥药Wegovy降价对财务造成"痛苦"影响，但旨在以价换量。为稳定信 心，公司宣布启动最高38亿丹麦克朗的股票回购，并计划派发股息，同时寄望于新款口服Wegovy片剂能推动未来增长。 丹麦制药巨头诺和诺德正面临近十年来最严峻的业绩挑战，公司预计2026年销售额将显著下滑，市场竞争正日趋激烈。 2月4日，公司CEO Mike Doustdar直言， 公司将在2026年遭遇"前所未有的定价压力"，明星减肥药Wegovy在美国的降价对财务影响"痛苦"， 但此举意在换取更广泛的市场覆盖与长期发展。 此前，诺和诺德发布的2026年业绩展望大幅低于市场预期 ，预计全年销售额按固定汇率计将下降5%至13%，远超分析师预期的约1.4%降幅。 悲观指引引发股价显著波动，财报公布后，纽交所上市的诺和诺德美国存托凭证盘中曾短暂暂停交易，恢复交易后，临近美股午盘时跌幅即超 过10%，收跌14.6%。悲观情绪在盘后持续传导至欧洲市场，其欧股股价下挫18%。 BMO资本市场分析师埃文·西格曼指出，虽然诺和诺德上一季度营收和利润均超出市场预期，但 "疲软的2026年业绩指引 ...

Core Viewpoint - Novo Nordisk's stock price has significantly dropped due to forecasts predicting a substantial decline in sales for 2026, facing its most severe performance challenges in nearly a decade amid intense market competition and U.S. drug pricing policies [1][3]. Sales Forecast - The company anticipates a sales decline of 5% to 13% for 2026, excluding currency effects, which is much worse than the analyst expectation of approximately 1.4% [1][4]. - This forecast indicates that Novo Nordisk will experience its first annual sales decline in nine years, the last being in 2017 due to a price war in the U.S. insulin market [3][4]. Market Challenges - CEO Mike Doustdar highlighted that the company will face pricing pressures in an increasingly competitive market, particularly due to the "Most Favored Nation" pricing policy initiated by former President Trump and the expiration of patents for semaglutide in several international markets [3][4]. - The U.S. market is seeing a shift in prescription trends and intensified competition, compounded by the negative impact of Medicaid reducing coverage for obesity medications [7]. Financial Performance - In 2025, Novo Nordisk reported a sales increase of 6% to 309.06 billion Danish kroner, slightly above analyst expectations, driven primarily by its obesity care business, which grew by 31% [10][13]. - The company's operating profit for 2025 was 127.66 billion Danish kroner, a slight decline of 0.5% year-on-year, but a 6% increase when adjusted for constant currency [10][13]. New Product Developments - Despite challenges, the approval of the oral version of Wegovy (semaglutide) is seen as a positive development, with early prescription volumes showing promising growth [14]. - Novo Nordisk plans to continue expanding Wegovy into more markets and is investing in research and development for future growth opportunities [9][14]. Shareholder Returns - In response to the stock price decline, Novo Nordisk's board has initiated a new share buyback program of up to 15 billion Danish kroner (approximately 2.4 billion USD) and proposed a final dividend of 7.95 Danish kroner per share for 2025 [18].

Core Viewpoint - Novo Nordisk's Q4 sales decreased by 7.6% year-on-year, yet still surpassed analyst expectations, with the weight loss drug Wegovy performing better than anticipated. The company forecasts its first annual sales decline in nine years for this year, with projected sales and operating profit for 2026 expected to drop by 5% to 13%, compared to analyst estimates of a 1.4% and 3.1% decline respectively [1][3][6]. Sales Performance - In Q4, sales amounted to 79.14 billion Danish Krone, down 7.6% year-on-year but above the analyst forecast of 76.9 billion Danish Krone. Wegovy's sales reached 21.86 billion Danish Krone, exceeding the expected 21.07 billion Danish Krone, while Ozempic's annual sales were 127.09 billion Danish Krone, also above the forecast of 124.87 billion Danish Krone [15][12]. 2026 Sales Guidance - Novo Nordisk's guidance for 2026 indicates a significant sales and operating profit decline of 5% to 13% on a constant exchange rate basis, which is much worse than the analyst expectation of a 1.4% sales decline and a 3.1% drop in operating profit. This unexpected guidance has caused a strong market reaction [6][3][8]. Market Challenges - The company faces multiple pressures, including increased competition in the U.S. market and the impact of the U.S. government's "Most Favored Nation" pricing policy, which is expected to significantly lower actual prices. Additionally, changes in prescription trends and Medicaid's reduction of coverage for obesity drugs are compounding these challenges [5][8][11]. International Market Outlook - While the global GLP-1 market is expected to continue expanding, the company will face challenges from increased competition and the expiration of patents for semaglutide in certain markets. Novo Nordisk plans to launch Wegovy in more markets in 2026 and introduce a 7.2mg dosage in several countries [11][6]. Shareholder Returns - In response to the challenging year, Novo Nordisk's board has initiated a new share buyback program of up to 15 billion Danish Krone (approximately 2.4 billion USD) and proposed a final dividend of 7.95 Danish Krone per share, bringing the total expected dividend for 2025 to 11.70 Danish Krone per share [20].

Group 1 - The core action taken by President Trump involves demanding 17 leading global pharmaceutical companies to propose concrete plans to lower drug prices in the U.S. within 60 days, or face government intervention [3] - Trump's letter emphasizes the implementation of the "Most Favored Nation" pricing policy, which aims to link U.S. drug prices to lower prices in other countries [3] - According to RAND Corporation, the average price of prescription drugs in the U.S. is typically 2-3 times higher than in other developed countries, and can be up to 10 times higher in some cases [3] Group 2 - Following the pressure from the government, some pharmaceutical companies, such as AstraZeneca, have begun to adjust their strategies by announcing price reductions for certain drugs in the U.S. [4] - Companies like Eli Lilly, Novo Nordisk, and Pfizer are exploring direct sales models as a response to the ongoing pricing pressures [4] - The pharmaceutical industry is preparing for potential tariffs on imported drugs, indicating that the pricing issue is part of a larger political and corporate struggle [4]

Core Viewpoint - The article discusses the potential impact of Trump's proposed drug pricing policies on the U.S. pharmaceutical industry, suggesting that while there are significant threats, the short-term effects may be limited due to existing structural challenges in the industry [1][2]. Group 1: Background and Current Situation - U.S. pharmaceutical spending is at a high level, with per capita drug spending reaching $1,564 in 2022, significantly higher than other developed countries. The compound annual growth rate (CAGR) from 2018 to 2022 was 6.2% [1]. - The increase in drug prices is primarily driven by innovative drugs, which have long-term pricing above inflation, while generic drugs continue to decrease in price. The complex pricing system supports the stability of high prices for innovative drugs [1]. - The U.S. pharmaceutical trade deficit is expanding, with imports projected at $213 billion and a deficit of $118.6 billion in 2024. Ireland has become a major source of this deficit due to tax advantages [1]. Group 2: Policy Implications - Trump's proposal for a "Most Favored Nation" (MFN) pricing policy aims to anchor U.S. drug prices to the lowest prices in developed countries, potentially reducing prices by 30%-80%. However, legal complexities may hinder its implementation, and the focus will likely remain on reforms within the Medicare framework [2]. - The Pharmacy Benefit Manager (PBM) system is identified as a structural monopoly that drives up drug prices, with rebate percentages for chronic diseases exceeding 50% and some reaching 80%. The top three PBMs control 80% of prescriptions, leading to a highly concentrated market [3]. - Trump's proposed 25% tariffs on European drugs aim to encourage domestic manufacturing, but the high costs and long construction timelines for U.S. production facilities may limit the effectiveness of this strategy in the short term [3].